A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart

Recruiting

Phase 4 Results N/A

Summary of Purpose

The purpose of this study is to determine if Apixaban is safer than a Vitamin K Antagonist given for 6 months in terms of bleeding in patients with an irregular heart beat (atrial fibrillation) and a recent heart attack or a recent procedure to open up a blood vessel in the heart. All patients would also be taking a class of medicines called P2Y12 inhibitors (such as clopidogrel/Plavix) and be treated for up to 6...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 27 November 2017.

4 Jun 2015 9 Apr 2015 27 Dec 2018 28 Dec 2018 1 Nov 2017 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Open Label
  • Endpoint: Safety Study
  • Intervention: Factorial Assignment

Contacts

  • Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:

    Clinical.Trials@bms.com

  • First line of the email MUST contain NCT# and Site #.

  • First line of the email MUST contain NCT# and Site #

See All